Background/Aims: Iron deficiency (ID) and iron deficiency anemia (IDA) are global health concerns associated with adverse perinatal effects. Despite efforts taken at the international level, there is no consensus on unified prevention/ treatment strategies, largely stemming from inconsistencies of outcome reporting. Our objective was to comprehensively assess outcome reporting perinatal iron intervention trials as Phase 1 of core outcome set (COS) development to inform future research. Methods: Systematic search in MEDLINE, EM-BASE, Cochrane Databases, and CINAHL (January 2000 -April 2016), with inclusion of trials involving pregnant or postpartum women with ID/IDA confirmed before recruitment. Articles were independently screened and selected by 2 reviewers; data were extracted in duplicate. Quality was assessed using published scoring systems. Outcome definitions and measurement methods were tabulated. Results: Of 7,046 citations, 33 randomized controlled trials were included. Sixtynine reported outcomes were categorized into 8 domains. High methodological quality characterized 25 (76%) studies. Reporting quality was low in 16 (49%), moderate in 13 (39%), and high in 4 (12%) studies. Variation was greatest for outcome definition, timing of assessment and measurement methods. Conclusion: This review identifies a comprehensive long-list of outcomes reported of perinatal iron interventions for ID/IDA. Beyond highlighting existing variation in outcome reporting, it provides a foundation for development of a COS for future trials.
Introduction
Anemia, a major public health concern in both lowand high-resource countries [1] , affects a quarter of the world's population, with considerable morbidity and mortality, specifically in pregnant women [2] . Pregnancy is an iron consumptive state, with nearly two-thirds of iron stores expanded on hemoglobin formation, of which iron is a key component [3] ; thus, women are at high risk of developing iron deficiency (ID) and ID anemia (IDA) perinatally. To account for physiologic anemia secondary to normal pregnancy adaptations, anemia in pregnancy has been defined as a hemoglobin below 11.0 g/dL in the first trimester, below 10.5 g/dL in the second and third trimesters, and below 10.0 g/dL postpartum [4, 5] . In 2011, the global prevalence of anemia in pregnancy was 38.2%, representing 32.4 million women, of whom 0.8 million were affected severe anemia, defined as a hemoglobin < 7.0 g/dL [5] . ID, is the most common nutritional deficiency worldwide [6] , and the most preventable cause of anemia [7] .
It has been estimated that nearly 50% of anemia in women of reproductive age can be ameliorated with appropriate iron supplementation [5] . Recently published guidelines highlight the importance of global efforts directed at prevention of IDA, particularly in vulnerable populations, with high prevalence [8] . However, multiple public health interventions have not managed to tackle the problem of IDA, partly owing to the inability to draw meaningful conclusions regarding effectiveness of proposed iron interventions, secondary to imprecision of study design, particularly in relation to outcome reporting. Systematic reviews on perinatal ID/IDA have previously highlighted variation in outcome reporting [9, 10] , and called for harmonization. This can be achieved through the development and implementation of a core outcome set (COS), understood to be the minimum requirement for outcome reporting for future studies of perinatal iron supplementation. A COS outlines the minimum outcomes for a research topic, agreed upon via consensus reached by relevant stakeholders, designed to standardize outcome reporting in randomized controlled trials (RCTs) to allow for comparison of data across studies, delineation of robust conclusions, and simplification of knowledge translation efforts [11] but does not limit researchers from including other outcomes of interest [12] .
The aim of this systematic review was to develop a comprehensive list of reported outcomes and to assess the quality of outcome reporting as the first phase in the development of a COS for use in future studies addressing iron interventions in perinatal ID/IDA.
Materials and Methods
A prospectively registered systematic review of RCTs was carried out to assess outcome reporting in studies of perinatal ID/IDA (PROSPERO CRD42016037333) [13] . The search was conducted using the OvidSP search platform in the following databases: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews, as well as the EBSCOHost search platform in CINAHL, including all articles indexed until April 1, 2016 (online suppl.Material Appendix S1; for all online suppl. material, see www.karger.com/ doi/10.1159/000495566). The search was limited to human data, English language publications from the year 2000 (to reflect outcomes of importance to contemporary researchers), and RCTs with greater than 10 participants. Studies were excluded if there was insufficient methodological detail preventing assessment of the quality of reporting. All references obtained from the search were imported into the Covidence [14] systematic review software. Additional articles were identified by hand searching reference lists of included studies. The review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines [15] .
Titles and abstracts were screened independently and concurrently by 2 reviewers (A.K.M. and M.M.), and included if they (i) involved pregnant women with ID or IDA, clearly defined a priori, and confirmed prior to recruitment; (ii) examined the role of any form of iron interventions; and (iii) were RCTs or controlled trials. The original study's definitions of ID and IDA were accepted if they included ferritin < 30 µg/L, transferrin saturation ≤15%, serum iron ≤5.4 µmol/L, and/or evidence of microcytosis with normal hemoglobin electrophoresis for the former, alongside Hb ≤11.0 g/dL for the latter [4, 16] . Animal studies were excluded. Two reviewers (A.K.M. and J.D.) independently screened and reviewed full texts of all included articles in parallel. Disagreements were resolved by discussion and consensus. Particulars of excluded studies, as well as rationale for exclusion, were recorded.
A piloted data extraction form was tested and data from the included studies were extracted in parallel by 2 independent reviewers (A.K.M. and J.D.). Data extraction included: journal name, country, publication year, scientific journal ranking (www.scimagojr.com), funding source, sample size, study population, definition of ID/IDA, types of interventions; outcomes included in the methods and results section and their definitions; measurement instruments used to assess the outcomes, quality assessment of study methodology and outcome reporting.
Quality assessment of the reported outcomes was based on a piloted adaptation of the assessment proposed in the Management of Otitis Media with Effusion in Cleft Palate (MOMENT) protocol [17] . This included the following: (1) was the primary outcome clearly defined? (2) was a precise definition of the primary outcome provided and were the measurement approaches for the primary outcome outlined (inclusive of the tools, methods, time points, time, place, and individual responsible for the measurement) in sufficient detail to allow reproduction? (3) were secondary outcomes identified? (4) were precise definitions for secondary outcomes provided? (5) was an explanation for the inclusion of selected outcomes provided? 6) were strategies to augment the quality of outcome measurements (i.e., training, repeated measurement) utilized when appropriate? Using this approach, the maximum score a study could receive was 6. Data were scored in-
Results
The search yielded 7,040 articles (search strategy presented in online suppl. Materials Appendix S1) and an additional 6 articles were identified through the screening of reference lists. Following removal of duplicates, 5,088 studies were included in the initial title and abstract screen, of which 631 full-text studies were assessed for eligibility, with 33 finally included in the review (Fig. 1 ). There were 26 studies of iron interventions in the antepartum period and 9 in the postpartum period.
Characteristics of the included studies are summarized in Table 1 . Most studies (15, 46%) originated in Asia (with 11 (33%) of these conducted in India), followed by Europe (8, 24%), Africa (4, 12%), Australia (4, 12%), South America (1, 3%), and North/Central America (1, 3%). Just over half of the studies (52%) were published in specialist journals, with content dedicated to research in the areas of hematology or obstetrics and gynecology. Commercial funding was disclosed in 18% of the included studies, while other funding sources were listed in 21%; with 61% of published studies providing no details of funding source.
Most studies (25, 76%) were of high methodological quality, based on the Jadad scale. The overall quality of outcome reporting, based on the MOMENT scale [17] , was low in 16 (49%), moderate in 13 (39%), and high in 4 (12%) of included studies (Fig. 2) . There was no correlation between methodological quality and quality of outcome reporting (Pearson's R 0.32, p = 0.07). Of the in- cluded studies, which identified the primary outcome, 33% incorporated a sample size calculation. Full details of outcome reporting in RCTs of iron interventions in the antepartum and postpartum period are summarized in Table 2 and detailed in online supplementary Materials Table S1. In the 26 studies conducted in the antepartum period, 69 distinct outcomes were reported, which were combined into 30 overall outcomes categorized across 8 domains. In the 9 studies conducted in the postpartum period, 32 individual outcomes were reported, which were combined into 21 outcomes over 8 domains (Fig. 3) . ++ Report on various outcomes of same study. * Both antepartum and postpartum, thus included in both. bid, twice a day; CRP, c-reactive protein; EI, elemental iron; Hb, hemoglobin; ID, iron deficiency; IDA, iron deficiency anemia; IM, intramuscular; IV, intravenous; MCV, mean corpuscular volume; LMW, low molecular weight; PO, oral; PP, postpartum; rhEPO, recombinant human erythropoietin; TIBC, total iron binding capacity; tid, three times a day; TSAT, transferrin saturation. 
Reporting of Hematologic Indices
Hematologic indices such as hemoglobin and serum ferritin were commonly reported outcomes in RCTs of iron interventions in pregnant and postpartum women ( Table 2) . Definitions of hematologic indices consisted solely of the unit of measurement (such as g/ dL, g/L), with variation introduced by use of both conventional and international systems (SI) of measure (such as µg/dL, µmol/L). Variation in reporting was encountered among all hematologic outcomes (Table 2) . For instance, hemoglobin, the most commonly reported outcome in the reviewed RCTs, was reported in the following ways: hemoglobin, proportion of patients reaching target hemoglobin, change in hemoglobin level, target hemoglobin achievement rate, correction of anemia, and incidence of anemia at the end of treatment.
Variation was seen across all domains in the timing of outcome measurement. For instance, the timing of hemoglobin measurement ranged from 1 to 13 weeks following the initiation of iron supplementation. Additionally, the description of the methods used for outcome measurement (specifics regarding how laboratory tests were conducted, which analyzers were used, how machines were calibrated, etc.) was lacking in up to 71% of studies reporting hematologic indices for iron intervention in the antepartum period.
Reporting of Clinical Outcomes
Clinical outcomes were divided into (i) maternal outcomes such as hospitalization, improvement in symptoms of anemia, quality of life, postpartum depression, and non-verbal intelligence; (ii) obstetric outcomes such as red blood cell transfusion, mode of delivery, preterm birth, hypertensive disorders of pregnancy, signs of placental insufficiency, placental weight, and breastfeeding; and (iii) neonatal outcomes such as gestational age at birth, birthweight, gender, Apgar scores, cord hemoglobin, cord ferritin, admission to the neonatal intensive care unit, neonatal death, mother-child interaction, and infant development.
Maternal outcomes were reported in 8-19% of studies included in this review; obstetric outcomes were reported in 4-27% of studies, while neonatal outcomes were reported in 4-35% of studies (Table 2) . Definitions were missing for 55-82% of clinical outcomes. Methods of measuring clinical outcomes (such as specifics regarding how gestational age was calculated, etc.) were missing in up to 81% of reported clinical outcomes.
Reporting of Safety and Acceptability Outcomes
Safety and acceptability outcomes included adverse events, safety, tolerability, adherence, and cost-effectiveness. Adverse events were described by 85% antepartum studies and 67% of postpartum studies. There was varia- tion in descriptions of the adverse event in the studies included in this review, with multiple synonyms used to describe a particular manifestation (Table 3) . For example, epigastric discomfort was described as epigastric discomfort (3 trials), dyspepsia (4 trials), gastritis (3 trials), gastric upset (1 trial), gastro-intestinal irritation (1 trial), digestive problems (2 trials), acidity (1 trial), and heartburn (3 trials). None of the studies provided specific definitions for these terms. While adherence was addressed by 50% of antepartum and 56% of postpartum studies, safety was addressed only by antepartum studies (12%), whereas tolerability and cost-effectiveness were addressed by 1 antepartum study each (Table 2) . Table S1 . Hb, hemoglobin; ID, iron deficiency; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; NICU, neonatal intensive care unit; PCV, packed cell volume; RBC, red blood cells. 
Discussion
Our systematic review is the first to comprehensively assess outcomes reported in trials of perinatal iron interventions for ID/IDA, providing an inclusive list of outcomes reported to date and their definitions, completing the Phase 1 of COS development. Through this review, we have demonstrated that studies addressing perinatal ID/ IDA are marked by significant variation in outcome reporting including (1) variable outcome definitions; (2) lack of clear outcome reporting, making replication or comparison of work challenging; (3) variation in timing of outcome measurement, without clear rationale for the chosen time-frames; and (4) lack of description of measurement tools used to assess the chosen outcomes. Moreover, studies preferentially focus on hematological indicators at the expense of clinical outcomes. Our findings complete the first phase of the COS in perinatal ID/IDA [11] , which has been registered with the Core Outcome Measures in Effectiveness Trials Initiative [53] .
We followed existing guidelines on conducting and reporting systematic reviews [15] . Our involvement of health service users in offering input into data synthesis in a systematic review of outcome reporting is novel. This input, allowed for cross-checking of the importance of reported outcomes beyond the perspectives of clinicians and researchers. To ensure our review accurately captures outcome reporting in RCTs, we conducted a sensitivity analysis of 12 excluded studies, which did not objectively assess ID or IDA prior to recruitment, one of our exclusion criteria. This analysis did not identify additional outcomes, demonstrating that our search strategy and inclusion criteria were sufficiently broad to capture all relevant outcomes, Original description of symptoms
Conceptual synthesis of symptoms
Feeling unwell (1) Malaise (3) Influenza-like symptoms (1) Weakness (1) Fever (3) Fever (5) Hyperthermia (2) Nausea (16) Nausea (16) Vomiting (11) Vomiting (11) Epigastric discomfort (3) Epigastric discomfort (21) Dyspepsia (4) Gastritis (3) Gastric upset (1) GI irritation (1) Digestive problems (2) Acidity (1) Heartburn (3) Abdominal pain (6) Abdominal discomfort (8) Abdominal discomfort (1) Abdominal cramps (1) Constipation (15) Constipation (15) Diarrhea (13) Diarrhea (13) Flatulence (1) Flatulence (1) Dark stools (1) Dark stools (1) Hypotension (7) Hypotension (8) Hypotensive shock (1) Anaphylaxis (3) Anaphylaxis (7) Anaphylactic reaction (3) Anaphylactoid reaction (1) Chest tightness (2) Chest tightness (2) Hypertension (1) Hypertension (1) Tachycardia (2) Dysrhythmias (3) Palpitations (1) Thromboembolism (1) Thromboembolism (1) Heat intolerance (1) Hot Flushes (7) Feeling warm (1) Hot flushes (2) Facial flushing (3) Original description of symptoms
Shivering (2) Shivering (2) Headache (6) Headache (6) Vertigo (2) Dizziness (5) Dizziness (3) Myalgia (1) Myalgia (2) Muscle cramps (1) Arthritis (1) Arthralgia (5) Arthralgia (3) Small joint stiffness (1) Rash (3) Rash (4) Skin eruption (1) Pruritus (2) Pruritus ( Non-specific (7) Discontinuation of treatment/ withdrawal from study (3) Failure of therapy (1) Hospitalization (1) Miscellaneous (7) Disability/incapacity (1) Threat to life (1) Overdose (1) Cancer (1) Death (1) resulting in a comprehensive summary of outcomes reported to date.
We limited the timeframe of our review to ensure assessment of outcomes relevant to the design of contemporary studies on the subject, and we feel that the 16-year timeframe of the review has allowed ample opportunity for the comprehensive identification of outcomes reported to date. We limited our review to RCTs for the following reasons: (i) there were sufficiently large numbers of existing studies of perinatal iron interventions, and (ii) our intention to develop a COS to be used in future RCTs of iron interventions in the perinatal period. The exclusion of other studies will mean that some, particularly longer-term outcomes more easily measured in observational studies, may be excluded from our review. However, given that the aim of a COS is to determine a minimum set of outcomes that must be reported in all future studies, it is unlikely that these longer-term outcomes, often not amenable to measurement within the scope of a RCT, would be included as mandatory items within a COS.
Our findings systematically present and assess the heterogeneity inherent within currently reported outcomes in studies on perinatal iron interventions highlighted in previous reviews and meta-analyses [9, 10, [54] [55] [56] [57] [58] . Our results demonstrate that hemoglobin and other hematologic indices were the most commonly reported outcomes in the literature. This is likely due to the accessibility, acceptability, and ease of testing of these outcome measures [59] . There is a multitude of studies demonstrating improvements in hematologic indices with iron supplementation for ID/IDA, with very few published findings on improvements in clinical outcomes [9] . In the absence of correlation studies demonstrating a link between hematological indices and clinical outcomes, this gap in evidence leaves clinicians without concrete guidance on the best strategies to address the global public health problem of anemia in pregnancy [60] . Furthermore, studies reporting only improvements in hematological indices do not account for outcomes, which health service users consider important [59] , but are often overlooked.
Differences in timing of outcome measurement are likewise problematic, preventing pooling of results and meta-analysis [9] . Physiologically, iron supplementation results in reticulocytosis 3-7 days after the start of treatment, and is followed by an increase in hemoglobin appreciable 2 weeks following the commencement of treatment [61] , typically at a rate of 0.1 g/dL per day [62] . In our review, measurements of hemoglobin levels occurred at a variety of time-points, ranging from 1 to 13 weeks following commencement of intervention, and were sometimes carried out at weekly intervals. Consensus regarding minimum timeframes at which hematologic parameters should be measured, reflective of the underlying physiologic processes, would be beneficial in future RCTs. Furthermore, the lack of detailed reporting of the methods used for outcome measurement limits reproducibility [63] . Clear descriptions of the instruments and conditions of measurement are necessary to allow study replication and confirmation of results [64] , permitting robust evidence synthesis and development of useful guidelines.
Several studies in our review reported composite outcomes, where several discrete outcomes are combined into a single entity [65] , the advantages and disadvantages of which are described elsewhere [65] . While the decision to use composite outcomes must be left to the discretion of trialists, clear reporting of each individual outcome forming the composite is necessary [66] .
An unexpected observation in our data was the overall poor quality of outcome reporting in studies of high methodologic quality. Only 45% of studies in our review specified a primary outcome and only 33% of these included a sample size calculation in the final publication. This is surprising, given the widespread dissemination of the Consolidated Standards of Reporting Trials statement and widely accepted standards for reporting of RCTs [67, 68] .
Also of importance in addressing efforts toward data harmonization is consideration of the heterogeneity inherent in the definitions of commonly reported derived clinical concepts, such as those of fetal growth restriction or preterm birth. The definitions and use of these clinical endpoints is an area currently under debate [69] [70] [71] . Suggesting appropriate definitions for these clinical outcomes is not within the scope of our review. However, the ongoing debate in this area highlights the necessity for publishing summary statistics and raw values for nonderived variables such as birth weight and gestational age in parallel to the publication of derived variables. Furthermore, where log scale transformations are necessary for data analysis, supplemental reporting of original values should be encouraged. Such requirements will promote consistency across studies, thereby enabling data collation and meta-analysis.
Finally, our review identified infrequent reporting of potential harms of iron interventions. There is evidence of a U-shaped curve for maternal hemoglobin concentration and its association with the risk of pregnancy-related morbidity, with postulation of several mechanisms by which high iron states may mediate these events, including oxidative stress, increased blood viscosity, and sub-optimally effective systemic response to inflammation and infection [72] . Two areas of ongoing inquiry are the role of iron in induction of oxidative stress and the association of iron with gestational diabetes [73] . There is some suggestion that iron supplementation increases oxidative stress in pregnancy [74] and that hyperglycemia and gestational diabetes are also potentially associated with a state of increased oxidative stress [75] . Studies evaluating possible associations between excess body iron stores, iron supplementation, and gestational diabetes have reported conflicting results [73] . Thus, reporting of harms in addition to proposed reporting of adverse events should be an inherent part of studies addressing iron interventions for perinatal ID/IDA.
Anemia in pregnancy is a major public health problem. To accurately assess the effectiveness of interventions, good quality and reproducible outcome reporting is essential. Beyond highlighting marked variation in outcome reporting among perinatal ID RCTs, our review has identified a long-list of reported outcomes and their definitions, which completes the first phase of COS development for use in future RCTs on the subject. This will enable the pooling of data, permitting the development of generalizable evidence-based guidelines, empowering clinicians to provide effective interventions for women with perinatal ID/IDA in high-and low-income countries.
